Tm Bioscience to use bioMerieux's gene content:
This article was originally published in Clinica
Tm Bioscience of Toronto, Ontario, has non-exclusively licensed gene content from Marcy l'Etoile, France-based diagnostics firm bioMerieux. The Canadian firm plans to incorporate bioMerieux's patented knowledge of Factor II (prothrombin) and Factor V Leiden genes in its Tag-It mutation detection kits for coagulation disorders, which it launched recently. Tm Bioscience estimates the DNA testing for coagulation disorders in Europe and the US to be growing at more than 50% annually.
You may also be interested in...
Europe's largest online pharmacy is calling for online sales of OTC medicines to be allowed in its home market Switzerland, to increase the supply of crucial products to help people manage the symptoms of COVID-19, such as headaches, fever, diarrhoea, coughs, colds or nausea.
Confusion is rife over low UK testing levels to confirm COVID-19 in health care staff and patients, and comparisons with measures taken in similar-sized economies have been unfavorable. Diagnostics manufacturers are not to blame, says the industry.
Novartis's Jakavi joins the likes of Roche's Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients.